DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $240,949 | +13.7% | 8,165 | -11.3% | 0.00% | – |
| Q1 2023 | $211,991 | -71.0% | 9,201 | -59.4% | 0.00% | -100.0% |
| Q1 2022 | $730,000 | -68.3% | 22,686 | -56.1% | 0.00% | -75.0% |
| Q4 2021 | $2,304,000 | -44.3% | 51,667 | -37.0% | 0.00% | -50.0% |
| Q3 2021 | $4,139,000 | -33.4% | 82,049 | +3.5% | 0.01% | -27.3% |
| Q2 2021 | $6,219,000 | +25.7% | 79,284 | -8.5% | 0.01% | +37.5% |
| Q1 2021 | $4,946,000 | -7.5% | 86,624 | +35.6% | 0.01% | -11.1% |
| Q4 2020 | $5,349,000 | +191.3% | 63,867 | +24.6% | 0.01% | +200.0% |
| Q3 2020 | $1,836,000 | +163.0% | 51,247 | +77.5% | 0.00% | +200.0% |
| Q2 2020 | $698,000 | +48.5% | 28,877 | +7.6% | 0.00% | 0.0% |
| Q1 2020 | $470,000 | -45.2% | 26,830 | -45.5% | 0.00% | 0.0% |
| Q4 2019 | $857,000 | -18.9% | 49,205 | -28.7% | 0.00% | 0.0% |
| Q3 2019 | $1,057,000 | +391.6% | 68,994 | +566.9% | 0.00% | – |
| Q2 2019 | $215,000 | – | 10,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |